Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Considering Lotronex Risk Management Advisory Cmte. Meeting For July

Executive Summary

FDA is considering another advisory committee meeting for GlaxoSmithKline's Lotronex to discuss potential risk management options that would allow renewed use of the irritable bowel syndrome agent.

You may also be interested in...



Rx Approval Times Depend On Amount, Not Source, Of FDA Funds, Study Says

Drug approval times are affected by the amount of funding but not the source of funds, a study published in Health Affairs finds

Rx Approval Times Depend On Amount, Not Source, Of FDA Funds, Study Says

Drug approval times are affected by the amount of funding but not the source of funds, a study published in Health Affairs finds

GSK Lotronex To Be Reviewed By FDA Drug Safety Cmte. In April

FDA's Drug Safety & Risk Management Subcommittee will review the safety of GlaxoSmithKline's withdrawn irritable bowel syndrome agent Lotronex (alosetron) on April 23

Related Content

UsernamePublicRestriction

Register

PS037952

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel